Stifel Financial has agreed to acquire the capital markets arm of Canadian investment bank GMP Capital in an all-cash transaction valued at nearly $52m.

The transaction excludes GMP’s US cannabis and certain clearing businesses.

GMP’s capital markets business includes advisory and underwriting, institutional sales and trading as well as research services.

The firm now plans to focus on its wealth management operations.

It is in negotiations to increase its stake to 100% in Canadian wealth manager Richardson GMP.

Currently, GMP has a 33% stake in Richardson GMP.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Tick here to opt out of curated industry news, reports, and event updates from Private Banker International.

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

GMP chairman of the board Don Wright said: “With this sale, the GMP Board intends to deploy the Corporation’s strong capital position to focus and invest heavily in wealth management where we see significant opportunities to partner with the Richardson family, our top performing investment advisers and management at Richardson GMP to create significant long term value for shareholders.”

The deal with Stifel has already secured the nod of the GMP board. It is now pending shareholder and regulatory approvals.

GMP CEO Harris Fricker and other key employees will move to Stifel post deal completion which is anticipated in the final quarter of this year.

Stifel chairman and CEO Ronald Kruszewski said: “Over the past 13 years, we have grown our annual institutional net revenues from roughly $60 million to more than $1 billion through a combination of strategic acquisitions and strong organic growth.

“The addition of GMP further enhances our institutional business given its strength in the Canadian markets and within the technology, healthcare, cannabis and energy verticals.”

Earlier this year, Stifel announced the acquisition of advisory firm Mooreland Partners.